10 Best Hospitals for Lung Cancer Treatment in the USA: Cost, Insurance, Specialists & Treatment Options

Lung cancer treatment can involve surgery, radiation, chemotherapy, targeted therapy, immunotherapy, or a combination of several approaches. The treatment plan depends on factors such as the type and stage of cancer, genetic characteristics of the tumor, and the patient’s overall health.

For people comparing hospitals, the decision goes beyond a hospital’s name or national reputation. Access to thoracic specialists, multidisciplinary cancer teams, clinical trials, advanced diagnostics, treatment technology, insurance coverage, and financial support can all matter. The hospitals below represent leading U.S. cancer centers identified through the 2026–2027 U.S. News & World Report cancer rankings and other oncology recognition cited in the source material. This is an editorial starting point for research, not a guarantee that one hospital will be better for every patient.

10 leading U.S. hospitals for lung cancer care

Hospital	Location	Notable lung cancer strengths
MD Anderson Cancer Center	Houston, TX	Thoracic oncology, clinical trials, immunotherapy research
Memorial Sloan Kettering Cancer Center	New York, NY	Precision oncology and targeted-treatment research
Mayo Clinic	Rochester, MN	Multidisciplinary care and advanced diagnostics
Dana-Farber Brigham Cancer Center	Boston, MA	Lung cancer research and molecularly targeted treatment
Massachusetts General Hospital	Boston, MA	Radiation oncology and personalized medicine
Johns Hopkins Hospital	Baltimore, MD	Thoracic surgery and research-driven cancer care
Hospital of the University of Pennsylvania	Philadelphia, PA	Immunotherapy and advanced oncology research
Northwestern Memorial Hospital	Chicago, IL	Thoracic surgery and precision medicine
Stanford Health Care	Stanford, CA	Minimally invasive surgery and early detection research
Mount Sinai Hospital / UCSF Medical Center	New York, NY / San Francisco, CA	Genomic testing and advanced radiology

The national cancer ranking cited in the source material places MD Anderson first, followed by Memorial Sloan Kettering, Mayo Clinic, Dana-Farber Brigham Cancer Center, Massachusetts General Hospital, Johns Hopkins, Hospital of the University of Pennsylvania, Northwestern Memorial Hospital, Stanford Health Care, and a tie involving Mount Sinai and UCSF.

The order should not be interpreted as a lung-cancer-specific guarantee. A hospital’s overall cancer ranking does not necessarily determine which center is most appropriate for a particular tumor or treatment plan.

How these hospitals were selected

The list is based primarily on the 2026–2027 U.S. News & World Report cancer rankings and oncology recognition referenced in the source material, along with information about lung cancer programs, treatment capabilities, research and clinical trials.

That approach is useful for identifying nationally recognized centers, but patients may have different priorities. Someone considering lung surgery may focus more heavily on thoracic surgical expertise. A person with advanced NSCLC may be more interested in molecular testing, targeted treatment or clinical-trial access.

1. MD Anderson Cancer Center — Houston, Texas

MD Anderson is identified as the leading hospital in the source ranking and has a substantial focus on complex cancer care and clinical research.

Its lung cancer program is particularly relevant for patients interested in clinical trials and newer systemic treatments, including immunotherapy. The center also has extensive thoracic oncology services, bringing together specialists involved in surgical, medical and radiation treatment.

Patients considering MD Anderson should ask which clinical trials are currently accepting patients, whether their pathology and molecular testing can be reviewed before the consultation, and which members of the thoracic cancer team would be involved in care.

2. Memorial Sloan Kettering Cancer Center — New York, New York

Memorial Sloan Kettering is ranked second in the source material and is particularly notable for its emphasis on precision oncology.

For lung cancer, that can mean studying the molecular features of a tumor to determine whether a targeted treatment or research study may be appropriate. MSK’s lung cancer research includes work involving genetic alterations such as EGFR and KRAS and investigational approaches to advanced disease.

For patients whose cancer has progressed after standard treatment, the hospital’s research program may also be relevant when evaluating clinical-trial options.

3. Mayo Clinic — Rochester, Minnesota

Mayo Clinic is ranked third in the source list and is known in the research material for complex multidisciplinary care and advanced diagnostics.

Lung cancer treatment can require input from several specialties, including thoracic surgery, medical oncology, radiation oncology, pulmonology, radiology and pathology. Coordinating those disciplines can be particularly important when a case involves several treatment options.

Patients researching Mayo Clinic may want to ask how the institution’s specialists will approach staging, molecular testing and the balance between local treatment and systemic therapy.

4. Dana-Farber Brigham Cancer Center — Boston, Massachusetts

Dana-Farber Brigham Cancer Center ranks fourth in the source list and has a strong research focus in lung cancer.

One area highlighted in the source material is research involving EGFR-mutant lung cancer, including clinical trials involving targeted therapies. Molecularly defined cancers can require a different treatment strategy from tumors without an actionable alteration.

For someone with NSCLC, asking whether comprehensive biomarker testing has been completed—and whether the results open the door to a targeted treatment or clinical trial—can be an important part of the consultation.

5. Massachusetts General Hospital — Boston, Massachusetts

Massachusetts General Hospital is ranked fifth in the source list. Its relevant strengths include radiation oncology, personalized treatment research and access to advanced radiation approaches.

Radiation treatment can be delivered in different ways depending on the tumor and treatment plan. The source material specifically highlights stereotactic body radiotherapy (SBRT) and proton therapy as advanced approaches used in selected circumstances.

Patients should ask why a particular radiation technique is being proposed and how it fits into the overall treatment plan rather than assuming newer technology is automatically more appropriate.

6. Johns Hopkins Hospital — Baltimore, Maryland

Johns Hopkins Hospital ranks sixth and has a strong emphasis on thoracic surgery and multidisciplinary cancer care.

Surgical treatment for lung cancer can vary considerably. Depending on the cancer, procedures may include removal of a small section of lung, segmentectomy, lobectomy, sleeve resection or more extensive surgery. Minimally invasive techniques, including video-assisted procedures and robotic approaches in selected cases, may also be considered.

The most useful discussion is not simply whether a hospital performs a particular operation, but which procedure is being proposed for the patient’s specific tumor and why.

7. Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania

The Hospital of the University of Pennsylvania ranks seventh in the source list and is included for its advanced oncology research, including work involving immunotherapy and cellular therapies.

For patients exploring newer treatment options, clinical-trial availability may be an important consideration. Eligibility depends on factors such as cancer type, stage, previous treatment and the specific requirements of the study.

Because trials open and close over time, patients should verify current availability directly with the cancer center.

8. Northwestern Memorial Hospital — Chicago, Illinois

Northwestern Memorial Hospital ranks eighth and is highlighted in the source material for thoracic surgery and precision medicine.

For patients whose treatment may include surgery, evaluation by a thoracic oncology team can help clarify whether surgery is appropriate and what surgical approach may be considered. Molecular testing may also influence the treatment plan, particularly for NSCLC.

A practical advantage for patients is the ability to evaluate surgical, medical and radiation options as parts of one broader treatment strategy rather than viewing them separately.

9. Stanford Health Care — Stanford, California

Stanford Health Care ranks ninth in the source list and is highlighted for minimally invasive robotic surgery and early-detection work.

Minimally invasive surgery can involve smaller incisions than traditional open procedures in appropriately selected patients. Whether that approach is suitable depends on the tumor’s location, extent and other clinical factors.

Patients considering Stanford should also ask about current clinical trials, molecular testing and the full range of treatment options available for their specific diagnosis.

10. Mount Sinai Hospital / UCSF Medical Center — New York, New York / San Francisco, California

Mount Sinai Hospital and UCSF Medical Center are presented as tied entries in the source ranking. They are separate institutions in different regions of the country, so patients should evaluate each center independently.

The source material highlights comprehensive genomic testing and advanced radiology. Those capabilities can be relevant when doctors are trying to characterize a tumor accurately and determine which treatment options may be appropriate.

Location can also make a practical difference. A patient comparing these two centers may need to weigh travel, lodging, follow-up visits and insurance network status alongside medical considerations.

Lung cancer treatment options worth understanding

The two broad types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatment choices depend heavily on the type and stage of disease.

Biomarker testing and targeted treatment

Modern treatment of NSCLC often involves molecular testing of the tumor. The purpose is to identify genetic alterations that may help guide treatment.

The source material identifies several important biomarkers, including:

• EGFR: A genetic alteration found in a portion of lung cancers and associated with targeted treatments such as osimertinib.
• ALK: An alteration that can occur in some patients, including some people who have never smoked or smoked very little. Targeted drugs include alectinib and lorlatinib.
• KRAS: A common alteration in lung cancer. The KRAS G12C variant can be treated with targeted therapies such as sotorasib.
• ROS1, BRAF, MET and RET: Less common alterations for which targeted treatments may be available.
• PD-L1: A protein marker rather than a mutation. Its expression can help doctors evaluate whether immunotherapy may be appropriate.

Not every patient will have one of these biomarkers, and finding an alteration does not automatically determine the entire treatment plan. The results need to be considered alongside stage, prior treatment and other clinical information.

Surgery

Surgery may play a central role for some patients with localized lung cancer. Depending on the tumor and surrounding structures, an operation may remove part of a lobe, an entire lobe or, in selected situations, more extensive tissue.

Procedures such as segmentectomy, sleeve lobectomy and minimally invasive or robotic-assisted surgery may be considered in appropriate cases. The objective is to remove the cancer while taking the patient’s anatomy and overall treatment plan into account.

Radiation therapy

Radiation may be used alone or alongside other treatments. Stereotactic body radiotherapy (SBRT) is designed to deliver highly focused radiation to a tumor, while proton therapy is another specialized technique that can be considered in selected cases.

The source material cites SBRT costs averaging about $53,133, but that figure should be viewed as an estimate rather than a standard price.

Chemotherapy and immunotherapy

Chemotherapy remains part of treatment for many lung cancer patients, while immunotherapy has become an important option for selected cancers. Checkpoint inhibitors work by helping the immune system recognize and attack cancer cells.

For advanced disease, treatment may continue for an extended period, making medication costs and insurance coverage especially important parts of the treatment discussion.

How much does lung cancer treatment cost?

Lung cancer care can be expensive, but there is no single price that applies across the United States. The source material estimates comprehensive treatment costs at $150,000 to more than $400,000, depending on stage and the treatments required.

Illustrative figures from the source include:

Treatment	Estimated cost
Surgery	$31,900–$80,000
Chemotherapy	$10,000–$30,000 per month
Radiation therapy	$15,000–$53,000 per course
Targeted therapy	$10,000–$15,000 per month
Immunotherapy	Often more than $150,000 per year

The same source estimates average treatment costs of about $25,000 for Stage 1 disease and more than $211,000 for Stage 4 treatment. These figures are broad estimates and should not be treated as quotes from a hospital.

A patient’s actual bill may be affected by the procedure, hospital, physician and anesthesia fees, length of stay, imaging, laboratory testing, rehabilitation, medication, complications and insurance coverage. Most importantly, a hospital’s charges are not necessarily the same as a patient’s out-of-pocket cost.

Insurance and Medicare coverage

Insurance can substantially reduce what a patient personally pays, but the details depend on the specific policy.

Under Original Medicare, Part A can cover certain inpatient hospital services, while Part B covers many outpatient services, including physician care, diagnostic services and certain cancer treatments. For covered Part B services, patients generally owe a share of the Medicare-approved amount after meeting the applicable deductible.

The source material specifically notes that Original Medicare does not have a general annual out-of-pocket maximum for Parts A and B. Medicare Advantage plans have annual out-of-pocket limits for covered services, although the exact rules and costs depend on the plan.

Medicare Part D can cover certain prescription drugs taken at home, including some oral cancer medicines, with costs determined by the individual plan.

Private insurance may involve deductibles, copayments and coinsurance. Network status and prior authorization can also affect what a patient pays.

Before starting treatment, patients should ask the insurer and hospital to confirm:

• Whether the hospital and relevant physicians are in network
• Whether the proposed treatment requires prior authorization
• What deductible remains
• What copayments or coinsurance apply
• What portion of the treatment is expected to be the patient’s responsibility

Financial assistance for lung cancer treatment

The financial burden can extend beyond medical treatment. Travel, lodging, deductibles, copays and other expenses may become significant, particularly for patients who travel to a major cancer center.

The source material identifies several organizations that may provide financial assistance, including CancerCare Co-Payment Assistance Foundation, Patient Advocate Foundation, HealthWell Foundation and Good Days. Available programs and eligibility requirements can change, so patients should verify current funding directly with each organization.

For travel-related needs, organizations such as the American Cancer Society’s Hope Lodge, Air Care Alliance and Mercy Medical Angels may provide or coordinate assistance for eligible patients.

Cancer centers may also have financial counselors or patient navigators who can help patients understand treatment estimates and available assistance programs.

What should you look for in a lung cancer hospital?

National recognition can be useful, but it should be only one part of the comparison. Readers researching hospitals may want to look at:

• Experience with the specific type and stage of lung cancer
• Access to thoracic surgeons, medical oncologists and radiation oncologists
• Availability of molecular and biomarker testing
• Relevant clinical trials
• Surgical and radiation treatment options
• Quality and safety information
• Insurance network status
• Expected out-of-pocket costs
• Rehabilitation and follow-up services
• Travel, lodging and ongoing-visit requirements

For a complicated diagnosis, obtaining a second opinion can also give patients another perspective on staging or treatment options.

Frequently asked questions

What is the best hospital for lung cancer treatment in the USA?

There is no single hospital that is best for every patient. The hospitals in this article are among the leading U.S. cancer centers identified by the cited 2026–2027 national cancer ranking, but the most relevant center depends on the patient’s diagnosis, treatment needs and access to appropriate specialists and trials.

How much does lung cancer treatment cost?

Treatment can range from tens of thousands of dollars for an individual therapy to several hundred thousand dollars for comprehensive care. Costs vary with cancer stage, treatment type, hospital charges, physician fees, medications and insurance coverage.

Does Medicare pay for lung cancer treatment?

Medicare can cover many medically necessary lung cancer services, but coverage depends on the treatment and the type of Medicare coverage. Patients should confirm their benefits, deductibles, coinsurance and network requirements before treatment.

Is biomarker testing necessary for lung cancer?

Biomarker testing can be especially important in NSCLC because certain genetic alterations may make targeted treatments available. The appropriate testing depends on the individual cancer and should be discussed with the oncology team.

Should I consider a second opinion?

A second opinion can be useful when treatment decisions are complex, surgery is being considered, or several approaches appear possible. It may also help identify clinical trials or targeted treatment options that deserve further discussion.

How can I find a lung cancer clinical trial?

Major cancer centers maintain their own clinical-trial programs, and patients can ask the oncology team whether any current studies match their diagnosis. Eligibility varies, so a trial that sounds relevant may not be appropriate for every patient.

Sources

• U.S. News & World Report 2026–2027 cancer rankings, as referenced in the source material.
• National Cancer Institute, lung cancer treatment information and biomarker resources.
• Medicare.gov, information on cancer treatment coverage under Medicare.
• MD Anderson Cancer Center, lung cancer and clinical-trial information.
• Memorial Sloan Kettering Cancer Center, lung cancer clinical trials and research.
• Dana-Farber Cancer Institute, EGFR-mutant lung cancer research and clinical trials.
• Mayo Clinic, lung cancer program information.
• Johns Hopkins Medicine, lung cancer treatment and thoracic surgery information.

Medical Disclaimer

This article is provided for general informational and educational purposes and is not personalized medical advice. Hospital rankings, treatment programs, clinical trials, costs, physician affiliations and insurance coverage can change. Readers should verify important information directly with hospitals, insurers and qualified healthcare professionals. The information here does not guarantee a particular treatment outcome. Emergency situations require immediate professional medical attention.